Other News To Note
Wednesday, April 18, 2012
Intellect Neurosciences Inc., of New York, entered a collaboration with the University California, Irvine, to test preclinical Alzheimer's disease vaccine candidate RV03. RV03 is a dual-acting peptide vaccine candidate designed to induce an immune response against beta amyloid and delta tau.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.